| Literature DB >> 27706093 |
Gilbert Kirsch1, Ahmed Bakr Abdelwahab2,3, Patrick Chaimbault4.
Abstract
In this review, we will present the different aspects of coumarins and derivatives, from natural origins or synthetically prepared, and their action on inflammation. Coumarins and also furo- and pyranocoumarins are found in many different plants. These compounds are very often investigated for antioxidant properties. Other biological properties are also possible and anti-inflammation activity is one of these. As coumarins are also available quite easily via synthesis, natural ones can be prepared this way but derivatives with special substituents are also feasible. A review on the same topic appeared in 2004 and our contribution will take into account everything published since then.Entities:
Keywords: coumarins; furocoumarins; inflammation; pyranocoumarins
Mesh:
Substances:
Year: 2016 PMID: 27706093 PMCID: PMC6273422 DOI: 10.3390/molecules21101322
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Natural coumarins.
Some anti-inflammatory activities of Simple coumarins.
| Cpd | CPE% 1 | IL-1β | IL-6 | 5-LOX | NF-κB | NO | TNF-α | Ref. |
|---|---|---|---|---|---|---|---|---|
| IC50: 6.6 2 | [ | |||||||
| <200 ng/mL (20 mg/kg) 3,** | <400 ng/mL (20 mg/kg) 3,** | [ | ||||||
| <3000 pg/mL (160 μg/mL, 24 h) 4,*; <1000 pg/mL (160 μg/mL) 5,** | Activity < 1 (160 μM) 4,* | <20 μM (160 μM) 4,** | <500 pg/mL (160 μg/mL, 24 h) 4,*; <400 pg/mL (160 μg/mL) 5,** | [ | ||||
| 39% (0.01 mmol/kg) | IC50: 72.5 nm | [ | ||||||
| <10 μM (10 μM) 6,* | [ | |||||||
| >80% (50 μg/mL) 1 | [ | |||||||
| <10% (50 μg/mL) 1 | [ | |||||||
| <5% (50 μg/mL) 7 | [ | |||||||
| 0% 6 | 0% 6 | 0% 6 | [ |
1 Carageenin paw edema in rat; 2 Arachidonic acid induced ear edema in mice; 3 LPS-stimulated mouse peritoneal macrophage; 4 LPS-stimulated BV2 microglia; 5 Aβ-stimulated BV2 microglia; 6 LPS-stimulated macrophage RAW264.7; 7 LPS-stimulated U937-3xxKB-LUC human monocytic cell line; kg is referring to the mice weight; % is referring to percentage of inhibition. * p < 0.05 versus negative control. ** p < 0.01 versus negative control.)
Figure 2Naturally occurring furocoumarins.
Some anti-inflammatory activities of furocoumarins.
| Cpd | COX-2 | IL-1β | IL-6 | IL-10 | NF-κB | NO | iNO | PGE2 | TNF-α | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|
| <40% | <20 pg/mL | <600 pg/mL | <600 pg/mL | <30 μM (10 μg/mL) 3,***; | <40% | <400 pg/mL | <40 μM | [ | ||
| IC50: 38.3 ± 1.7 μM 3,*** | [ | |||||||||
| IC50: 10.7 μM 5 | IC50>20 μg/mL 3, 28.1% ± 39.7% | [ | ||||||||
| <20% (20 μg/mL) 3,**** | 92.4% | [ | ||||||||
| <60% at 50 μM 6,* | IC50: 9.8 μg/mL 3; 85.3% ± 8.7% | <5 μM | <10 ng/mL | [ |
1 PMACI induced of HMC-1 cells; 2 LPS-induced of BALF (broncoalveolar lavage fluid); 3 LPS-stimulated macrophage RAW264.7'; 4 Carageenin paw edema in rat; 5 In bone marrow-derived mast cell (BMMC); 6 IL-1β induced of A549 cells; kg is referring to the mice weight; % is referring to percentage of inhibition; * p < 0.05 versus negative control; ** p < 0.01 versus negative control; *** p < 0.001 versus negative control; **** p < 0.005 versus negative control.
Figure 3Naturally occurring pyranocoumarins.
Some anti-inflammatory activities of pyranocoumarins.
| Cpd | COX-2 | IL-1β | IL-6 | NF-κB | NO | iNO | PGE2 | TNF-α | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| <20% (30 μM) 1,*** | <40% (30 μM) 1,*** | <20 μM (30 μM) 1,***; <40 μM (30 μM) 2,** | <20% (30 μM) 1,*** | <40% (30 μM) 1,*** | [ | ||||
| <100 pg/mL (25 μg/mL) 1,** | <100 pg/mL | <15 μM (25 μg/mL) 1,** | <10000 pg/mL (25 μg/mL) 1,* | [ | |||||
| <60% (50 μM) 1,*** | <4000 RFU (50 μM) for NF-κB-dependent alkaline phosphate (SEAP ) 1,*** | <60% (50 μM) 1,*** | <60% (50 μM) 1,*** | [ | |||||
| <8000 RFU (60 μg/mL) 1,** | <20 μM (60 μM) 1,*** | <500 pg/mL (60 μM) 1,*** | [ |
1 LPS-stimulated macrophage RAW264.7; 2 SNP induced macrophage RAW264.7; % is referring to percentage of inhibition; * p < 0.05 versus negative control; ** p < 0.01 versus negative control; *** p < 0.001 versus negative control.
Figure 4Synthetic coumarins and derivatives.
Figure 5Synthesis of paracetamol modified coumarins.
Some anti-inflammatory activities of synthetic coumarins.
| Cpd | COX-2 | CPE% 3 | IL-6 | LOX | NO | iNO | TNF-α | Ref. |
|---|---|---|---|---|---|---|---|---|
| 69 (3 h); 60 (6 h) * | [ | |||||||
| <600 pg/mL (1 μM/kg) 1,* | <1200 pg/mL (1 μM/kg) 1,* | [ | ||||||
| −8 ± 17.4 (10 μM) 2; 37 ± 15.2 (100 μM) 2 | IC50: 10 μM 2; 33 ± 4.6 (10 μM) 2; 89 ± 0.7 (100 μM) 2 | IC30: 30 μM 2; | 58 ± 5.5 (10 μM) 2; 99 ± 0.1 (100 μM) 2 | [ | ||||
| 29 ± 7.8 (10 μM) 2 ; 57 ± 1.6 (100 μM) 2 | IC50: 24 μM 2; | IC50: 21 μM 2; | 47 ± 7.2 (10 μM) 2; 97 ± 0.6 (100 μM) 2 | [ | ||||
| 48.7 (0.1 mmol/kg, 3.5 h) | 89.8% (1 mM) | [ | ||||||
| 54 (0.1 mmol/kg, 3.5 h) | No (1 mM) | [ |
1 LPS induced alveolar macrophage; 2 J774 macrophage stimulated by LPS; 3 Carageenin paw edema in rat; kg is referring to the mice weight; % is referring to percentage of inhibition. * p < 0.05 versus negative control.